tirzepatide o semaglutide vs Tirzepatide, which is better for you? Comparison of Clinical Efficacy and

However, the data currently available suggests that continued treatment with these drugs is required for these weight losses to become sustainable

Virtual and in-person consultations available

Both have trade-offs worth understanding before the first injection

The SELECT trial (Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity), a phase 3 study involving 17,604 adults with overweight or obesity and pre-existing CVD but no diabetes, revealed that once-weekly subcutaneous semaglutide 2.4 mg reduced the risk of major adverse cardiovascular events by 20% compared with placebo over a mean follow-up of 39.8 months, including cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke [48]

However, each has distinct characteristics and potential applications